PO.ET01.06 · 实验与分子治疗
Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance
- 3166 3166 HER2驱动的非小细胞肺癌在微小残留病阶段的TKI适应性耐药可通过细胞表面靶向疗法进行靶向 TKI adaptive resistance in HER2-driven non-small cell lung cancer at minimal residual disease stage can be targeted using cell surface-directed therapies Manale El Kharbili, Daniel Wilkinson, Lauren Giesy, Sharon R. Pine, Peter Fecci, Kyle Concannon
-
- 3168 3168 针对与曲妥珠单抗不同的HER-2结构域的全人源抗HER-2抗体作为抗体药物偶联物用于抑制肿瘤生长 Fully human anti-HER-2 antibodies to HER-2 domains distinct from trastuzumab as antibody drug conjugates for tumor growth inhibition Ginette Serrero, Jianping Dong, Jun Hayashi
-
- 3170 3170 CDK4/6抑制性和抗缺氧miRNA-6883脂质纳米颗粒与铁死亡诱导剂或MEK抑制剂联合应用于乳腺癌和结直肠癌临床前模型 Combination of CDK4/6 inhibitory and anti-hypoxia miRNA-6883 lipid nanoparticles with ferroptosis inducers or MEK inhibitors in preclinical breast and colorectal cancer models Connor Purcell, Leiqing Zhang, Maryam Ghandali, Shulan Holmes-Farley, Audrey Yimin Su, Anais Sidonia, Ameen Raissi, Mackenzie Barrette, Emile Youssef, Theresa M. Raimondo, Wafik S. El-Deiry
- 3171 3171 多靶点激酶抑制剂LCI139通过利用内源性和外源性凋亡途径克服患者来源非小细胞肺癌类器官的化疗耐药 Multitargeted kinase inhibitor LCI139 overcomes chemotherapy resistance in patient-derived non small cell lung cancer organoids by harnessing intrinsic and extrinsic apoptosis Anna Ivanina Foureau, Nadeem Wajih, Cody C. McHale, Hailey L. Dryden, Sara Muhiczukic, Dhananjaya Pal, Bharath Yada, David Foureau, Fei Guo, Raj Dhupar, Donald Durden, Konstantinos Votanopoulos, Shay Soker, Eleftherios Markis, Kathryn Mileham
- 3172 3172 XYD-8006：一种新型ADAM9靶向双载荷ADC在胃肠道和肺癌模型中表现出优越的临床前疗效 XYD-8006: A novel ADAM9-targeting dual-payload ADC demonstrates superior preclinical efficacy in gastrointestinal and lung cancer models Weng Hang Ho, Pengfei Rong, Mengrui Zhao, Jun Li, Xidong Zhang, Hui Ding, Fangxing Ouyang
- 3173 3173 XYD-295和XYD-338：新型亲水性位点特异性连接子平台助力下一代双载荷ADC具备更强的疗效和安全性 XYD-295 and XYD-338: Novel hydrophilic site specific linker platform enables next generation dual payload ADCs with enhanced efficacy and safety Weng Hang HO, Pengfei Rong, Mengrui Zhao, Jun Li, Xidong Zhang, Hui Ding, Fangxing Ouyang, Jun Wang, Jiangcheng Xu, Yang Liu, Jiawang Liu, Kyoungwoo Lee
-
- 3175 3175 MUC1-C（XYA02）与MUC1-N（PankoMab，DS-3939a类似物）抗体偶联药物在临床前NSCLC中的疗效比较 Comparative efficacy of MUC1-C (XYA02) and MUC1-N (PankoMab, DS-3939a analog) antibody-drug conjugates in preclinical NSCLC Surender Kharbanda, Rehan Ahmad, Changchuin Mao, Sourav Choudhary, Brian Lawney, Govind Panchamoorthy, Ravi Jasuja
- 3176 3176 双特异性抗MUC16×抗DR5抗体IMV-M™通过MUC16引导的DR5（TNFRSF10B）聚集实现肿瘤选择性消退 Tumor-selective regression through MUC16-guided DR5 (TNFRSF10B) clustering by the bispecific anti-MUC16×anti-DR5 antibody IMV-M™ Iosif M. Gershteyn, Viktor Goldmakher
-
- 3178 3178 抗叶酸ADC——一种具有明确差异化作用机制的靶向治疗新型连接子-药物平台 Antifolate ADCs, a novel linker-drug platform for targeted therapy with a clear differentiating mechanism of action Ronald C. Elgersma, Renier C. Heijkants, Eline M. Loosveld, Noortje Veen, Chiel A. J. van der Horst, Iris van de Wetering, Arne J. Bramer, Erik Swiers, Tijl Huijbregts, Mike M. Ruth, Monique van der Vleuten, Gerard J. A. Rouwendal, Miranda M. C. Van der Lee, Benno Ingelse, Patrick H. Beusker, Wim H. A. Dokter
-
- 3180 3180 ATL-024，一种靶向肿瘤特异性糖肽表位CA242（CanAg）的新型拓扑异构酶I类ADC，在结直肠癌和胰腺癌模型中展现出强效活性和优异的安全性特征 ATL-024, a novel topoisomerase I-based ADC targeting the tumor-specific glycopepitope CA242 (CanAg), demonstrates potent activity in colorectal and pancreatic cancer models, and excellent safety profile Warren Viricel, Edouard Leroy
- 3181 3181 突变型p53特异性的TAZ/TEAD通路依赖性作为三阴性乳腺癌的治疗机会 Mutant p53-specific TAZ/TEAD pathway dependency as a therapeutic opportunity for triple-negative breast cancer Lydia Sakala, Yining Zhang, Jin G. Park, Joshua LaBaer
- 3182 3182 FLT3抑制剂quizartinib抑制WT1驱动的KIT-STAT5-PIM信号通路激活并诱导FLT3野生型HL-60细胞凋亡 The FLT3 inhibitor quizartinib suppresses the WT1-driven activation of the KIT-STAT5-PIM signaling pathway and induces apoptosis in FLT3-wild type HL-60 cells Hideaki Yamauchi, Naoko Hosono, Takahiro Yamauchi
-
-
- 3185 3185 SCR-A019：一种靶向MSLN的首创双互补位ADC，搭载新型拓扑异构酶I抑制剂，在临床前模型中显示出令人鼓舞的疗效 SCR-A019, a first-in-class biparatopic ADC targeting MSLN, with a novel topoisomerase I inhibitor demonstrates encouraging efficacy in preclinical models Qiong Wang, Yayuan Fu, Qi Deng, Chunlei Xia, Hui Zheng, Youfu Chu, Renhong Tang
- 3186 3186 MDM2敲低增强细胞周期进程中MCM2的磷酸化 MDM2 Knockdown Enhances Phosphorylation of MCM2 during Cell Cycle Progression Nikita Meghani, Viola Ellison, Jill Bargonetti
- 3187 3187 用于评估KRAS抑制剂疗效的患者来源类器官筛选平台 A patient-derived organoid screening platform for evaluating KRAS inhibitor efficacy Merel Derksen, Yasmine Abouleila, Mariana Martins Costa Silva, Gerben ten Hag, Rene Overmeer, Farzin Pourfarzad, Fabian Stavenuiter, Robert G. J. Vries, Sylvia F. Boj
